Financial due diligence on an insurer: the analyst's checklist

# Financial due diligence on an insurer: the analyst's checklist

In 2005, Hurricane Katrina exposed a hard truth: several insurers with strong headline balance sheets turned out to be leaning on reinsurers who couldn't or wouldn't pay in full. The insurers looked solvent on paper. The paper was wrong. Twenty years later, the same forensic questions apply, whether you are buying shares in a listed carrier, underwriting a private equity acquisition, or extending credit to an insurance group.

Insurance balance sheets are opinions dressed as numbers: reserves are estimates of future claims, and "assets" often depend on a counterparty's promise to pay. Financial due diligence (FDD) on an insurer is the discipline of testing those opinions before you rely on them. This lesson gives you a repeatable checklist.

Why insurer due diligence is different

A bank's balance sheet risk is mostly about assets going bad. An insurer's risk runs both ways: assets (investments) can lose value, but liabilities (reserves for future claims) can also turn out to be understated. That second risk is harder to see and easier to hide.

Two regulatory regimes anchor the numbers you'll be checking:

• United States: state-based regulation coordinated by the National Association of Insurance Commissioners (NAIC), using Risk-Based Capital (RBC) requirements and statutory accounting principles (SAP).
• European Union: Solvency II, the harmonized prudential framework enforced by national regulators (e.g., Germany's BaFin, France's ACPR) under guidance from EIOPA, the European Insurance and Occupational Pensions Authority.

Both regimes require insurers to hold capital against risk and to disclose it, but the accounting mechanics differ enough that cross-border comparisons need adjustment. Keep that in mind before comparing a US insurer's RBC ratio directly to a European insurer's Solvency Capital Requirement (SCR) coverage ratio.

Checklist item 1: reinsurance recoverables

Reinsurance is insurance that insurers buy from other insurers (reinsurers) to offload part of their risk. A recoverable is the amount the primary insurer expects to collect from the reinsurer once a claim is paid.

What to check:

• Concentration: how much recoverable sits with a single reinsurer? A book overly reliant on one weaker reinsurer is fragile.
• Counterparty rating: is the reinsurer rated A- or better by AM Best, S&P, or Moody's? Below that, recoverables deserve a haircut in your own model.
• Collateral: for offshore or unrated reinsurers (common in Bermuda-based sidecars or captive structures), is the exposure collateralized through trusts or letters of credit?
• Aging: recoverables outstanding for more than 90 days signal potential disputes.

Worked example: an insurer reports $500 million in reinsurance recoverables. If $150 million sits with a reinsurer rated BBB, a conservative analyst might apply a 20% haircut to that tranche, roughly $30 million, reducing effective recoverable assets to $470 million. That adjustment can meaningfully change your view of net tangible equity.

Checklist item 2: regulatory correspondence

Insurers are examined regularly. Do not just read the last filed statement; read what the regulator said about it.

• NAIC financial exams and market conduct exams in the US are public in most states and reveal whether reserves, claims handling, or governance were flagged.
• Solvency II Own Risk and Solvency Assessment (ORSA) reports and supervisory review letters in Europe can reveal capital add-ons imposed by regulators, a strong signal that the regulator sees more risk than the SCR ratio suggests.
• Look for consent orders, cease-and-desist actions, or fines, especially around claims practices or reserve adequacy.
• Check for going-concern qualifications or auditor management letters flagging internal control weaknesses.

A capital ratio that looks fine but sits next to a regulatory capital add-on is not fine. Treat correspondence as the annotated footnotes to the official number.

Checklist item 3: related-party transactions

Insurance groups are often complex webs of holding companies, reinsurance captives, and affiliated asset managers. Related-party transactions are deals between entities under common control, and they are a classic place to hide weak economics.

Key questions:

• Does the insurer cede a large share of premium to an affiliated reinsurer (common in private equity-owned life insurers), and on what terms? This can shift risk (and profit) off the regulated entity's books.
• Are investment management fees paid to an affiliated asset manager above market rate?
• Are there intercompany loans or surplus notes that inflate statutory capital without real external capital?
• Do dividends upstreamed to a holding company strip the operating insurer of capital right before a rating review or acquisition close?

This is not automatically fraud; affiliated reinsurance and captives are legal and widely used (Bermuda has built an entire industry on it). But undisclosed or off-market terms shift risk from the entity you are buying to one you cannot see.

Checklist item 4: rating agency actions

AM Best, S&P Global Ratings, Moody's, and Fitch assign financial strength ratings (FSR) to insurers, an independent read on claims-paying ability.

Do not just read the current rating. Read the trajectory:

• Outlook (positive, stable, negative) signals direction over the next 12 to 24 months.
• Rating actions history: a downgrade from A to A- in the past year, even if "stable" now, tells you something changed.
• Rating agency report text, usually free on the agency's site or via the insurer's investor relations page, explains *why*: reserve strengthening, reinsurance dependence, catastrophe exposure, or parent company stress.

A useful public resource for understanding how these ratings are constructed is AM Best's ratings methodology overview.

Putting it together: a mini worked screen

Say you're assessing a mid-size US personal lines insurer for acquisition.

| Check | Finding | Read |

|---|---|---|

| Reinsurance recoverables | $200M total, $60M with a B++ rated reinsurer, uncollateralized | Apply haircut, flag concentration |

| Regulatory correspondence | State market conduct exam cited slow claims payment in prior year | Reputational and potential remediation cost risk |

| Related-party | 30% of premium ceded to affiliated Cayman reinsurer, terms undisclosed | Request full treaty terms before proceeding |

| Rating action | AM Best moved outlook to negative six months ago | Confirms deteriorating trend, cross-check with reserve development |

None of these four items alone is disqualifying. Together, they form a pattern: reserve or reinsurance quality concerns, echoed independently by a regulator and a rating agency, and obscured partly through affiliated transactions. That convergence is the signal experienced FDD teams look for.

For reserve adequacy specifically, one added technique: compare incurred-but-not-reported (IBNR) reserve development over the last five years. IBNR is money set aside for claims that have happened but haven't yet been reported. If actual claims consistently come in higher than reserved (adverse development), the insurer has a pattern of underreserving, a leading indicator worth more than a single year's ratio.

# Simple reserve development check (illustrative)
reserves_booked_year1 = 100  # $M, booked at year-end
actual_paid_plus_case_reserves_3yrs_later = 118  # $M, true cost once matured

adverse_development = actual_paid_plus_case_reserves_3yrs_later - reserves_booked_year1
development_ratio = adverse_development / reserves_booked_year1

print(f"Adverse development: ${adverse_development}M ({development_ratio:.0%})")
# Output: Adverse development: $18M (18%)